Helius Medical Technologies Inc has a consensus price target of $10 based on the ratings of 4 analysts. The high is $24 issued by Roth MKM on March 5, 2024. The low is $1 issued by Maxim Group on December 20, 2022. The 3 most-recent analyst ratings were released by Roth MKM, Maxim Group, and Roth Capital on March 5, 2024, December 20, 2022, and August 23, 2022, respectively. With an average price target of $10 between Roth MKM, Maxim Group, and Roth Capital, there's an implied 1269.86% upside for Helius Medical Technologies Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Helius Medical Tech (NASDAQ:HSDT) was reported by Roth MKM on March 5, 2024. The analyst firm set a price target for $24.00 expecting HSDT to rise to within 12 months (a possible 3187.67% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Helius Medical Tech (NASDAQ:HSDT) was provided by Roth MKM, and Helius Medical Tech maintained their buy rating.
There is no last upgrade for Helius Medical Tech
The last downgrade for Helius Medical Technologies Inc happened on November 15, 2021 when Noble Capital Markets changed their price target from N/A to N/A for Helius Medical Technologies Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Helius Medical Tech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Helius Medical Tech was filed on March 5, 2024 so you should expect the next rating to be made available sometime around March 5, 2025.
While ratings are subjective and will change, the latest Helius Medical Tech (HSDT) rating was a maintained with a price target of $5.00 to $24.00. The current price Helius Medical Tech (HSDT) is trading at is $0.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.